This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Exubera Success May Hinge on Usability

Ryan, who has a buy rating on Pfizer, said "many doctors" believe some patients will have trouble gauging their ideal dose when inhaling Exubera. The best potential customers will be "motivated patients who were new to insulin therapy," she said. Ryan doesn't own shares, but her firm has provided services to Pfizer.

Several researchers at the ADA convention pointed out that technology improves over time, and that's been the case for insulin administration. Where once big needles were used for injections, now there are much smaller devices and pumps. The first insulin pump was the size of a backpack. Now, they're as small as cell phone or pagers.

As for insulin inhalers, Pfizer and Nektar will be pressed to improve Exubera not only for greater patient convenience, but also because of competition. Several companies are testing devices resembling anything from a cell phone to an asthma inhaler. Some potential competitors appear to offer "sleeker devices and more convenient administration," Arnold says.

The closest competitors are believed to be at least two to three years behind Exubera. Among the other hopefuls are Eli Lilly (LLY - Get Report), Alkermes (ALKS - Get Report) MannKind (MNKD) and Novo Nordisk (NVO).

Attempts at creating an inhaled insulin are nothing new. In 1925, German scientists reported on experiments that showed patients would need to inhale too much insulin for this approach to be effective, said Lutz Heinemann, CEO of business development at the Profil Institute for Metabolic Research in Neuss, Germany.

Speaking at the ADA meeting, he said each version of inhaled insulin will be different because of how the drug is formulated and how the delivery system works, and they can't be compared accurately without head-to-head tests. Heinemann has been a consultant to many diabetes-research companies.

Pfizer is supporting its Exubera launch with an extensive education campaign for doctors and patients, an effort it started soon after the Food and Drug Administration approved the drug on Jan. 27. Exubera is set to be available starting in mid-July.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALKS $63.33 0.00%
LLY $73.58 0.00%
NKTR $11.09 0.00%
PFE $34.53 0.00%
AAPL $123.25 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs